INVEST in ELIAZ THERAPEUTICS

Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®

elizTherapeutics · Sent/Recd. by ✉ ⊞ ⊟

Highlights

Targeting a $62B sepsis treatment market in the USA alone, part of a $147B global market

Our technology shuts down the sepsis process within hours to large animal models

Platform technology with potential applications beyond sepsis, including cancer and kidney disease

Over 60 patients across 52 countries varying our innovative technology

Second 2 phase/phase III pivotal trial, randomized, double-blind, placebo-controlled

Strategic partnerships with Toronto BC for development and commercialization of Eliaz's product

Collaboration with a global diagnostics company to support device clinical trials

Addressing critical unmet need: first significant advancement in sepsis treatment in 20 years

Featured Investors

Andrew Crane Managing Partner	Invested $500,000 ⊞
Crane Venture Partners is a venture capital firm focusing on life science, health care, and digital technology investments.	
Kevin Kimberlin Partner	Invested $500,000 ⊞
Kevin Kimberlin Partners is a venture capital firm focusing on life science, healthcare, and technology investments.	
Russell L. Brand Partner	Invested $250,000 ⊞
Russ Brand is a businessman, and experienced corporate director. Current and former positions include Board Member/Director, as he focuses on internship opportunities for students.	

As FDA approved, transformative, and patented scientific advisor to Cardiff University and Director of Medical Microbiology at the Hussman Institute for Autoimmunity, Dr. Isaac Eliaz

Dr. Eliaz is a board certified doctor of medicine, specializing in integrative medicine. He has treated patients for over 30 years, and has been a leader in the field of integrative medicine. He is the co-inventor of the patented XGal-3 immunotherapeutic platform, which is being developed for the treatment of sepsis, and other inflammatory diseases, and cancer. Dr. Eliaz is also the Medical Director of Healthcare Associates, a medical practice with offices in Beverly Hills and Santa Monica, California. Because it is an animal derived product, XGal-3 is not subject to the FDA's lengthy and expensive drug approval process, and can be marketed as a medical device. Dr. Eliaz's current research focuses on the use of the XGal-3 immunotherapeutic platform for treatment of sepsis.

Our Team



Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®

Why Eliaz Therapeutics?



Dr. Isaac Eliaz

Board certified doctor of medicine specializing in integrative medicine practice for over 30 years. Inventor of the patented XGal-3 immunotherapeutic platform and hematology therapeutics.

For over three decades, I've dedicated my life to innovating healthcare solutions that prioritize patient safety and effectiveness. My journey began with conventional medicine, but my frustration with its limitations led me to explore alternative paths, and I discovered a wealth of new, evidence-based methods that consistently delivered better results for my patients.

The cornerstone of my work has been a groundbreaking immunotherapy platform I pioneered several years ago, initially focused on treating inflammatory conditions. This led to a significant breakthrough: the discovery of a specific molecule, XGal-3, that plays a crucial role in the body's natural response to inflammation and tissue damage.

Our patented immunotherapy, supported by 2 prestigious NIH grants and protected by over 60 patents across 52 countries, has the potential to stop sepsis in its tracks. It does this by neutralizing the harmful inflammation that triggers sepsis and its rapidly advancing towards clinical trials.

Last year, mesothelioma, an previous tumor, was successfully acquired by a pharmaceutical company, demonstrating the significant interest in novel cancer and kidney the value in the healthcare sector. As an investor in Eliaz Therapeutics, you're not just supporting a groundbreaking cure for sepsis, you're investing in a thriving company with a proven track record of success.

Thank you for your support, Isaac Eliaz

THE PROBLEM

Sepsis is a Silent Killer That Claims 11 Million Lives Every Year

> 10. The crime of Nero, I do not even approaching a comparison with the great crime of Claudius Caesar. Tacitus, Annals, Book XIV

11 MILLION
lives lost to sepsis globally each year
Sepsis cost the U.S. healthcare system
$62B ANNUALLY

Sepsis strikes without warning, claiming a life every 14 seconds. Despite its devastating impact, it remains largely overlooked in public health discussions. Survivors face a lifetime of challenges, including chronic immunologic health responses, leading to rapid organ failure and death.

Throughout my career, I've witnessed sepsis devastate countless patients and families. This deeply ingrained experience has fueled my dedication to finding a solution. Studies on the U.S. healthcare system, I current treatments only manage symptoms, leaving the underlying cause untreated. This is why I developed XGal-3, a novel immunotherapy that aims to address the root cause of sepsis, offering a new hope for effective treatment. Our XGal-3 immunotherapy offers a drugless approach to combat this prevalent, life-threatening condition.

Our patented technology, supported by 2 prestigious NIH grants and protected by over 60 patents across 52 countries, has the potential to stop sepsis in its tracks. It does this by neutralizing the harmful inflammation that triggers sepsis and its rapidly advancing towards clinical trials.

Last year, mesothelioma, an previous tumor, was successfully acquired by a pharmaceutical company, demonstrating the significant interest in novel cancer and kidney the value in the healthcare sector. As an investor in Eliaz Therapeutics, you're not just supporting a groundbreaking cure for sepsis, you're investing in a thriving company with a proven track record of success.

THE OPPORTUNITY

Introducing XGal-3®: A New Hope for Sepsis Patients

With XGal-3®, we're creating a future where sepsis is no longer a death sentence.

XGal-3 is a medical device that works like digitals but with a crucial difference. It's derived from a specific molecule found in the body, making it a natural, effective solution. Unlike other treatments that rely on synthetic drugs, XGal-3 offers a drugless approach. By disrupting the pathological cascade, XGal-3 aims to prevent organ failure and death, ultimately saving lives and reducing healthcare costs. This innovative approach tackles the root cause of sepsis, offering a new hope for effective treatment.

HOW IT WORKS


INFECTION
INFLAMMATION
SEPSIS
DEHYDRATED
DEHYDRATED
XGAL-3
XGAL-3
XGAL-3